Frequently Asked Questions

SAMe 200 mg plus Lactobacillus plantarum HEAL9 1 × 10^9 CFU once daily improved self-rated depressive symptoms more than placebo in adults with subthreshold or mild-to-moderate depressive symptoms over 6 weeks. The primary endpoint, change in Zung Self-Rating Depression Scale (Z-SDS) total score at week 6, favored the combination (P = .0165), and the Z-SDS core depression subdomain also improved more than placebo (P = .0247). An earlier between-group benefit was already present at week 2 for Z-SDS total score (P = .0330).

The study found an early signal by 2 weeks. Compared with placebo, the combination produced a greater reduction at treatment week 2 in Z-SDS total score (P = .0330), the Z-SDS cognitive subdomain (P = .0133), the Z-SDS anxiety subdomain (P = .0459), and the Zung Self-Rating Anxiety Scale total score (P = .0345). The authors concluded that the combination showed fast and clinically relevant effects after 2 weeks of intake.

The anxiety findings were mixed but favored the combination early in treatment. At week 2, SAMe plus Lactobacillus plantarum HEAL9 improved the Z-SDS anxiety subdomain (P = .0459) and the Zung Self-Rating Anxiety Scale total score (P = .0345) more than placebo. However, the between-group difference in Zung Self-Rating Anxiety Scale total score was not significant at the end of treatment at week 6 (P = .3418).

No. In the exploratory analysis within the active-treatment group, baseline Z-SDS total score did not influence the degree of symptom reduction at the end of treatment, with Spearman ρ = 0.01 and P = .9684. Within the enrolled range of subthreshold to mild-to-moderate symptoms, the observed improvement did not appear to depend on initial symptom severity.

Not clearly. The analysis of change from baseline to the end of treatment on the other questionnaires showed no statistically significant between-group differences. A greater reduction in the Birmingham IBS symptom questionnaire total score was seen with the combination, but it did not reach statistical significance (P = .0854).

The combination was well tolerated over 6 weeks, and no treatment-related adverse events were reported. Adverse events occurred in 1 subject receiving placebo and 2 subjects receiving the combination, but these events were judged unrelated to study products. In the safety population of 89 subjects, no unblinding occurred, and compliance of at least 80% was recorded for 95.6% of treated patients.

The studied regimen was 1 oral tablet daily for 42 consecutive days. Each active tablet contained SAMe 200 mg plus Lactobacillus plantarum HEAL9 at 1 × 10^9 CFU, taken with a small amount of water, preferably without food.

The trial enrolled adults aged 18 to 60 years with recurrent mild-to-moderate depressive disorders according to ICD-10/F33 criteria and a baseline Zung Self-Rating Depression Scale raw score of 41 to 55. Patients were recruited from 10 Italian general practitioners, and 90 patients were randomized: 46 to SAMe plus Lactobacillus plantarum HEAL9 and 44 to placebo.

This was a 6-week randomized, double-blind, placebo-controlled trial, which supports a controlled comparison between the active combination and placebo. The primary outcome was the change from baseline to week 6 in Zung Self-Rating Depression Scale total score, analyzed with analysis of covariance. The results are most directly applicable to short-term treatment of adults with subthreshold or mild-to-moderate depressive symptoms in a primary care setting, using patient-reported outcome measures.

The main limitations were the relatively small sample size, the short 6-week treatment period, and the use of the Zung Self-Rating Depression Scale without a professional psychiatric evaluation. The authors also noted that no long-term conclusions can be drawn and that this is the only study so far evaluating this specific combination, with no reported dose-response data or data on use alongside antidepressant medications.